SNTI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Senti Biosciences Inc (SNTI) is not a strong buy for a beginner, long-term investor at this time. The company is in the early stages of clinical trials, with no significant revenue and a deteriorating financial performance. While there are some positive catalysts, such as FDA designations and analyst optimism, the lack of strong technical signals, poor financials, and no clear trading trends suggest holding off on investment until further developments.
The MACD is positive and expanding, suggesting a mild bullish trend. However, RSI is neutral at 69.077, and moving averages are converging, indicating no strong directional signal. The stock is trading near its resistance level (R1: 0.984), which could limit upside potential in the short term.
SENTI-202 received Orphan Drug and Regenerative Medicine Advanced Therapy designations from the FDA. Analyst raised the price target to $13, citing encouraging efficacy and durability signals in clinical trials. Participation in the Cell & Gene Live event highlights innovation in gene circuit-based cell therapy.
The company's cash runway remains a concern, as noted by analysts. Financial performance is weak, with a significant drop in net income (-37.21% YoY) and EPS (-89.06% YoY). No significant insider or hedge fund trading trends, and no recent congress trading data.
In Q3 2025, the company reported no revenue growth (0% YoY) and a net income loss of -$18.13M, down 37.21% YoY. EPS dropped significantly to -0.69 (-89.06% YoY), indicating worsening financial health.
Chardan raised the price target to $13 from $12 and maintained a Buy rating, citing encouraging clinical trial data. However, concerns about the company's cash runway were also highlighted.
